Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Theravance Biopharma (TBPH) over the last 4 years, with Jun 2025 value amounting to $50.7 million.

  • Theravance Biopharma's Shares Outstanding (Diluted Average) rose 4.06% to $50.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $50.7 million, marking a year-over-year increase of 4.06%. This contributed to the annual value of $48.8 million for FY2024, which is 11.67% down from last year.
  • Theravance Biopharma's Shares Outstanding (Diluted Average) amounted to $50.7 million in Q2 2025, which was up 2.05% from $49.7 million recorded in Q1 2025.
  • In the past 5 years, Theravance Biopharma's Shares Outstanding (Diluted Average) ranged from a high of $76.3 million in Q2 2022 and a low of $48.3 million during Q1 2024.
  • In the last 3 years, Theravance Biopharma's Shares Outstanding (Diluted Average) had a median value of $50.2 million in 2025 and averaged $53.1 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first increased by 16.67% in 2022, then dropped by 24.85% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Shares Outstanding (Diluted Average) stood at $69.5 million in 2021, then climbed by 5.95% to $73.6 million in 2022, then dropped by 24.85% to $55.3 million in 2023, then declined by 11.67% to $48.8 million in 2024, then grew by 4.06% to $50.7 million in 2025.
  • Its last three reported values are $50.7 million in Q2 2025, $49.7 million for Q1 2025, and $48.8 million during Q4 2024.